Clinical-stage biotech developing targeted therapies for RAS-pathway cancers, a common oncogenic driver in tumors.
Clinical-stage biotech developing targeted therapies for RAS-pathway cancers, a common oncogenic driver in tumors.
Has no approved product and no sales, so its spending is funded by raising money from investors, and everything rests on trial results and regulatory decisions for a small set of drugs aimed at RAS-pathway tumours. The lead drug, naporafenib, is in pivotal testing.
Moat: none (IP / patents). Clinical-stage biotech with no approved products; value rests on pipeline data.
Headquarters: San Diego, California, US · Founded: 2018 · Employees: 103
Size Erasca (ERAS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.83B, the 1198th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.76 on 18 Nov 2026.
Performance Over six months the shares gained 23.7%, against +10.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Capital Return on invested capital runs 52.9 points below its cost of capital (8.5% WACC).
Short interest Short interest is 10.6% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.89M | -$3.11M | -$3.81M | -$3.73M | -$2.64M |
| EBITDA | -$175M | -$128M | -$149M | -$138M | -$245M |
| Net income | -$308M | -$125M | -$162M | -$125M | -$243M |
| Free cash flow | -$109M | -$95.6M | -$109M | -$103M | -$118M |
| Capital expenditure | $132,000 | $128,000 | $60,000 | $1.77M | $14.6M |
| Total debt | $43.4M | $47.1M | $51.9M | $55.9M | $55.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Erasca ERAS | $4.83B | +24% | n/a | n/a | n/a | n/a |
| Revolution Medicines RVMD | $34.6B | +6% | n/a | -853% | 162.6× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Verastem VSTM | $866M | +66% | +650% | -194% | 8.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ERAS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.9% | +0.2% | 5th lowest of 21 |
| 6-month return | +23.7% | +10.4% | 3rd highest of 21 |
| Distance from 52-week high | -43.3% | -24.4% | 3rd lowest of 21 |
| ROIC minus cost of capital | -52.9 pp | +5.1 pp | 2nd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 7.6× | 17.3% | +19.9% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 1.6× | -8.8% | +3.0% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 10.2× | 26.4% | +5.5% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 2.2× | 1.7% | +6.2% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 4.5× | 15.9% | +12.7% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 4.6× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 6.8× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 7.8× | 5.0% | +192.5% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | 5.0× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 0.6× | 1.3% | +4.0% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 4.8× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 1.9× | 1.7% | -2.6% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 6.5× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 3.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 16.6× | 7.9% | +46.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 5.8× | 12.4% | +9.7% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 7.6× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 2.0× | -5.0% | +3.2% |